Male hormonal contraceptives

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 9, 2001, Pages 1389-1398

  Anawalt, B D ^a   Amory, J K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen; Gonadotropin releasing hormone antagonists; Gonadotropins; Male contraception; Progestin; Spermatogenesis; Testosterone

Indexed keywords

ACYLINE; ANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LONG ACTING DRUG; LUTEINIZING HORMONE; MALE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRESTOLONE; UNCLASSIFIED DRUG;

ATHEROGENESIS; AZOOSPERMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTRACEPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPLANT; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FAMILY PLANNING; HORMONAL REGULATION; HUMAN; INJECTION PAIN; MALE; NONHUMAN; PREGNANCY RATE; REVIEW; SIDE EFFECT; SPERMATOGENESIS; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

CONTRACEPTIVE AGENTS, MALE; CONTRACEPTIVES, ORAL, HORMONAL; HUMANS; MALE; PROGESTERONE CONGENERS; SPERMATOGENESIS; TESTOSTERONE CONGENERS;

EID: 0034850696     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.9.1389     Document Type: Review

References (48)

1. Contraceptive efficacy of testosterone-induced azoospermia by testosterone enanthate in normal men
2. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men
3. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception
4. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate
5. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies
6. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men
7. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men
8. Intramuscular testosterone undecanoate with or without oral levonorgestrel: A randomized placebo-controlled feasibility study for male contraception
9. Testosterone buciclate (20 Act-1) in hypogonadal men: Pharmacokinetics and pharmacodynamics of the new long-acting ester
10. Potential of testosterone buciclate for male contraception: Endocrine differences between responders and non-responders
11. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men
12. Pharmacokinetics and pharmacodynamics of testosterone pellets in man
13. Suppression of human spermatogenesis by testosterone implants
14. Efficacy and acceptability of testosterone implants, alone or in combination with a 5-α reductase inhibitor, for male hormonal contraception
15. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active
16. An oral regimen of cyproterone acetate and testerone for spermatogenic suppression in men
17. The therapeutic potential of testosterone patches
18. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception
19. Androgel
20. Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: A potential alternative to testosterone for androgen replacement and male contraception
21. Pharmacokinetics and pharmacodynamics of 7α-methyl-19-nortestosterone and intramuscular administration in healthy men
22. 7α-methyl-19-nortestosterone (MENT): The optimal androgen for male contraception and replacement therapy
23. Gonadotrophin and testosterone suppression by 7α-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men
24. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g] quinolines
25. Discovery of a potent orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6g]-quinoline (LG121071)
26. Selective androgen receptor modulators: A novel approach to androgen therapy for the new millennium
27. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido
28. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate
29. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens
30. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone
31. Acyline: A potent new gonadotropin-releasing hormone (GnRH) antagonist without side effects
32. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor
33. Progesterone-testosterone trials for male contraception
34. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: A promising male contraceptive approach
35. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot
36. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive
37. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations
38. Oral progestogen combined with testosterone as a potential male contraceptive: Additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism
39. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression
40. Low dose of cyproterone acetate and testosterone enanthate for contraception in men
41. Potential of norethisterone enanthate for male contraception: Pharmacokinetics and suppression of pituitary and gonadal function
42. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception
43. Potential impact of hormonal male contraception: Cross cultural implications for development of novel preparations
44. Results of a pilot study of the time to azoospermia after vasectomy in Mexico City
45. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5α-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone
46. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by the addition of finasteride
47. Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (macaca fascicularis)
48. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men